华纳药厂盐酸异丙肾上腺素注射液获批

Group 1 - The core point of the article is that Hunan Warner Pharmaceutical Co., Ltd. has received a drug registration certificate for Isoproterenol Hydrochloride Injection, marking its 10th drug registration certificate this year, bringing the total to 81 [2] - Isoproterenol Hydrochloride Injection is used for treating cardiogenic or infectious shock and complete atrioventricular block, and it is a common emergency medication included in the list of "clinically essential and easily short-supplied drugs" [2] - Warner Pharmaceutical is now the seventh domestic company to hold a production license for injection drugs, which enhances its product variety in formulations [2] Group 2 - The raw material drug Isoproterenol Hydrochloride has been approved for market launch as of October 2025, with both the raw material and formulation receiving an "A" rating in the review process [3] - The company aims to leverage its "raw material and formulation integration" advantage to enhance the cost quality and competitive edge of its formulation products, thereby improving its core competitiveness [3] - This development is expected to further meet public health needs and industry chain demands [3]